Akebia Therapeutics, Inc.盘中异动大幅拉升5.44%报2.04美元

市场透视2025-01-18

北京时间2025年01月18日02时10分，Akebia Therapeutics, Inc.（AKBA.us）股票出现异动，股价快速上涨5.44%。截至发稿，该股报2.04美元/股，成交量428.997万股，换手率1.97%，振幅5.70%。最近的财报数据显示，该股实现营业收入37.43百万美元，净利润-20.04百万美元，每股收益-0.10美元，毛利22.90百万美元，市盈率-9.23倍。机构...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2504118780?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-01-18 02:10","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2504118780","market":"us","top_or_hot":-1,"title":"Akebia Therapeutics, Inc.盘中异动 大幅拉升5.44%报2.04美元","media":"市场透视","content":"<div>\n<p>北京时间2025年01月18日02时10分，Akebia Therapeutics, Inc.（AKBA.us）股票出现异动，股价快速上涨5.44%。截至发稿，该股报2.04美元/股，成交量428.997万股，换手率1.97%，振幅5.70%。最近的财报数据显示，该股实现营业收入37.43百万美元，净利润-20.04百万美元，每股收益-0.10美元，毛利22.90百万美元，市盈率-9.23倍。机构...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250118021004a225ec1d&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Akebia Therapeutics, Inc.盘中异动 大幅拉升5.44%报2.04美元</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAkebia Therapeutics, Inc.盘中异动 大幅拉升5.44%报2.04美元\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-01-18 02:10 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250118021004a225ec1d&s=b><strong>市场透视</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>北京时间2025年01月18日02时10分，Akebia Therapeutics, Inc.（AKBA.us）股票出现异动，股价快速上涨5.44%。截至发稿，该股报2.04美元/股，成交量428.997万股，换手率1.97%，振幅5.70%。最近的财报数据显示，该股实现营业收入37.43百万美元，净利润-20.04百万美元，每股收益-0.10美元，毛利22.90百万美元，市盈率-9.23倍。机构...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250118021004a225ec1d&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LENZ","symbol_name":"Therapeutics","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250118021004a225ec1d&s=b","article_id":"2504118780","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250118021004a225ec1d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2504118780","pubTimestamp":1737137404,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"北京时间2025年01月18日02时10分，Akebia Therapeutics, Inc.股票出现异动，股价快速上涨5.44%。截至发稿，该股报2.04美元/股，成交量428.997万股，换手率1.97%，振幅5.70%。Akebia Therapeutics, Inc.股票所在的制药行业中，整体跌幅为1.49%。其相关个股中，Im Cannabis Corp.、Inmed Pharmaceuticals Inc.、和黄医药涨幅较大，Cbdmd, Inc.、大自然药业、Painreform Ltd.较为活跃，换手率分别为21.31%、14.10%、10.91%，振幅较大的相关个股有Cbdmd, Inc.、Alvotech C/Wts 、Aytu Biopharma, Inc.，振幅分别为21.41%、15.00%、12.44%。Akebia Therapeutics, Inc.公司简介：Akebia Therapeutics Inc是一家综合性生物制药公司。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LENZ":"Therapeutics","BK4139":"生物科技","AKBA":"Akebia Therapeutics, Inc."},"translate_title":"Akebia Therapeutics, Inc. jumped 5.44% to $2.04 in intraday movements","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LENZ":1,"AKBA":1},"content_text":"北京时间2025年01月18日02时10分，Akebia Therapeutics, Inc.（AKBA.us）股票出现异动，股价快速上涨5.44%。截至发稿，该股报2.04美元/股，成交量428.997万股，换手率1.97%，振幅5.70%。最近的财报数据显示，该股实现营业收入37.43百万美元，净利润-20.04百万美元，每股收益-0.10美元，毛利22.90百万美元，市盈率-9.23倍。机构评级方面，在所有3家参与评级的机构中，100%的券商给予买入建议，无券商给予持有、卖出建议。Akebia Therapeutics, Inc.股票所在的制药行业中，整体跌幅为1.49%。其相关个股中，Im Cannabis Corp.、Inmed Pharmaceuticals Inc.、和黄医药涨幅较大，Cbdmd, Inc.、大自然药业、Painreform Ltd.较为活跃，换手率分别为21.31%、14.10%、10.91%，振幅较大的相关个股有Cbdmd, Inc.、Alvotech C/Wts (To Pur Com)、Aytu Biopharma, Inc.，振幅分别为21.41%、15.00%、12.44%。Akebia Therapeutics, Inc.公司简介：Akebia Therapeutics Inc是一家综合性生物制药公司。该公司的经营部门是开发和商业化用于肾脏疾病患者的新疗法。该公司目前的产品组合包括Auryxia(铁柠檬酸盐)，一种在美国批准并上市的药物，用于控制透析依赖性慢性肾病成人患者的血清磷水平和治疗缺铁性贫血，用于非透析依赖性慢性肾病成人患者，Vafseo (vadadustat)，一种口服缺氧诱导因子脯氨酰羟化酶抑制剂。HIF-PH抑制剂在日本被批准用于治疗成人慢性肾脏疾病引起的贫血，处于临床前开发阶段。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。）","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2504118780","isCrawlerRequest":true}

Akebia Therapeutics, Inc.盘中异动 大幅拉升5.44%报2.04美元

精彩评论

Akebia Therapeutics, Inc.盘中异动大幅拉升5.44%报2.04美元